In this review, we will discuss different therapeutic approaches towards achieving this goal within the context of chronic lymphocytic leukemia (CLL), a cancer type with a p53-deficient subset that remains challenging to treat. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.